目的 探討鐵皮楓斗顆粒聯(lián)合枸櫞酸莫沙必利片治療慢性萎縮性胃炎的臨床療效。方法 選取2020年2月—2021年4月平頂山市直機(jī)關(guān)醫(yī)院收治的104例慢性萎縮性胃炎患者，使用隨機(jī)數(shù)字表法將所有患者分為對(duì)照組和治療組，每組各52例。對(duì)照組口服枸櫞酸莫沙必利片，5 mg/次，3次/d。治療組在對(duì)照組基礎(chǔ)上溫水沖服鐵皮楓斗顆粒，3 g/次，3次/d。兩組患者連續(xù)治療3個(gè)月。觀察兩組的療效，比較兩組萎縮、腸化生程度和血清表皮生長因子（EGF）、轉(zhuǎn)化生長因子β₁（TGF-β₁）、基質(zhì)金屬蛋白酶9（MMP-9）、胃蛋白酶Ⅰ（PGⅠ）、胃蛋白酶Ⅱ（PGⅡ）、胃泌素17（G-17）水平。結(jié)果 治療后，治療組患者的總有效率為96.15%，明顯高于對(duì)照組的84.62%，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組萎縮、腸化生程度均顯著改善（P<0.05）；治療組的萎縮、腸化生程度的改善程度優(yōu)于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組的血清EGF、TGF-β₁、MMP-9水平顯著降低（P<0.05），治療組血清EGF、TGF-β₁、MMP-9水平降低更明顯（P<0.05）。治療后，兩組的PGⅠ、PGⅡ、G-17水平均顯著升高（P<0.05），以治療組PGⅠ、PGⅡ、G-17水平升高更明顯（P<0.05）。結(jié)論 鐵皮楓斗顆粒聯(lián)合枸櫞酸莫沙必利片可提高慢性萎縮性胃炎的治療效果，減輕萎縮、腸化生程度，能延緩胃纖維化進(jìn)程，調(diào)節(jié)胃腸激素的分泌，安全性良好。

Objective To investigate the clinical efficacy of Tiepi Fengdou Granules combined with Mosapride Citrate Tablets in treatment of chronic atrophic gastritis. Methods Patients (104 cases) with chronic atrophic gastritis in Pingdingshan Municipal Hospital from February 2020 to April 2021 were divided into control and treatment groups using random number table, and each group had 52 cases. Patients in the control group were po administered with Mosapride Citrate Tablets, 5 mg/time, three times daily. Patients in the treatment group were po administered with Tiepi Fengdou Granules on the basis of the control group, 3 g/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and atrophy, intestinal metaplasia, and the levels of EGF, TGF-β₁, MMP-9, PGⅠ, PGⅡ, and G-17 in two groups were compared. Results After treatment, the total effective rate of the treatment group was 96.15%, which was significantly higher than 84.62% of the control group (P < 0.05). After treatment, the degree of atrophy and intestinal metaplasia were significantly improved in both groups (P < 0.05). The improvement of atrophy and intestinal metaplasia in the treatment group was better than that in the control group (P < 0.05). After treatment, the serum levels of EGF, TGF-β₁, and MMP-9 in two groups were significantly decreased (P < 0.05), and the serum levels of EGF, TGF-β₁, and MMP-9 in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the levels of PGI, PGII, and G-17 in two groups were significantly increased (P < 0.05), and the levels of PGI, PGII, and G-17 in the treatment group were significantly higher than those in the control group (P < 0.05). Conclusion Tiepi Fengdou granule combined with Mosapride Citrate Tablets can improve the therapeutic effect of chronic atrophic gastritis, delay the process of gastric fibrosis, regulate the secretion of gastrointestinal hormones, and reduce the degree of atrophy and intestinal metaplasia with good safety.

R975

河南省醫(yī)學(xué)科技攻關(guān)計(jì)劃項(xiàng)目（2018020280）